Week in Review: Sanofi Acquires Kadmon, a US-China Pharma, for $1.9 Billion

Deals and Financings   France 's Sanofi will acquire Kadmon, a New York city pharma with a China JV and a newly approved graft-versus-host drug, in a $1.9 billion deal; Frontage  Shanghai , a division of US-China CRO Frontage Holdings, acquired a 70% stake in Wuhan Heyan Biomedical Technology, a discovery CRO; Bio-Thera Solutions out-licensed US, EU and Canadian commercial rights for its Avastin biosimilar to Sandoz; Huadong Medicine entered a partnership with Insilico Medicine, a Hong Kong AI drug discovery company, to develop small-molecule oncology candidates;  Covid-19 Pandemic   Brii Biosciences of Beijing committed an additional $100 million for global regulatory filings and commercialization of its SARS-CoV-2 combination therapy; Chengdu Clover Biopharma received a permit to manufacture its S-Trimer COVID-19 vaccine candidate at its Changxing facility; Sinovac Biotech said a third dose of its SARS-CoV-2 vaccine improved the protection of CoronaVac® by 60%, including protection from the Delta variant;  Trials and Approvals   JW Therapeutics, a Shanghai CAR-T company, was approved to launch its anti-CD-19 CAR-T to treat large B-cell lymphoma in  China .  Stock Symbols: (NSDQ: KDMN) (SHA: 688177) (SHZ: 000963) (NSDQ: SVA) (HK: 2126)